Moreover, the side effects of antibody-based therapies in treatment of IBD, such as serious infection and malignancy after administration of anti-TNF antibody, has long been observed and are still significant concerns of current IBD clinicians, which may limit the application of this type of therapies (26, 27). This evidence concerns the gene TNF and inflammatory bowel disease.